Clinuvel Pharmaceuticals Limited (ASX: CUV) has announced that US FDA has granted marketing approval to use SCENESSE® for the treatment of EPP (erythropoietic protoporphyria) patients in the US.
- SCENESSE® is the first global systemic photoprotective drug for the treatment of patients with EPP;
- SCENESSE® acts as a potent anti-oxidative and melanogenic agent providing pan dermal (total surface) photoprotection;
- This genetic disorder causes absolute light intolerance and forces patients to lead an indoor or nocturnal existence.
At AEST 1:09 PM, the stock was trading at $39.490 per share, up by 40.584% from its previous close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.